The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 16, 2013
Filed:
Dec. 14, 2010
Eric R Prossnitz, Albuquerque, NM (US);
Sergey E Tkatchenko, San Diego, CA (US);
Chetana M Revankar, Arlington, VA (US);
Larry a Sklar, Albuquerque, NM (US);
Jeffrey B Arterburn, Las Cruces, NM (US);
Daniel F Cimino, Tijeras, NM (US);
Tudor I Oprea, Albuquerque, NM (US);
Cristian-george Bologa, Albuquerque, NM (US);
Bruce S Edwards, Albuquerque, NM (US);
Alexandor Kiselyov, San Diego, CA (US);
Susan M Young, Albuquerque, NM (US);
Eric R Prossnitz, Albuquerque, NM (US);
Sergey E Tkatchenko, San Diego, CA (US);
Chetana M Revankar, Arlington, VA (US);
Larry A Sklar, Albuquerque, NM (US);
Jeffrey B Arterburn, Las Cruces, NM (US);
Daniel F Cimino, Tijeras, NM (US);
Tudor I Oprea, Albuquerque, NM (US);
Cristian-George Bologa, Albuquerque, NM (US);
Bruce S Edwards, Albuquerque, NM (US);
Alexandor Kiselyov, San Diego, CA (US);
Susan M Young, Albuquerque, NM (US);
STC.UNM, Albuquerque, NM (US);
Abstract
The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ERα and ERβ). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors. Diseases which are mediated through one or more of these receptors include cancer (particularly breast, reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometreitis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disoders such as Parkinson's disease and Alzheimer's disease, as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.